PERADES: Defining Genetic, Polygenic and Environmental Risk for Alzheimer's Disease using multiple powerful cohorts, focussed Epigenetics and Stem
Lead Research Organisation:
CARDIFF UNIVERSITY
Department Name: School of Medicine
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
- CARDIFF UNIVERSITY (Lead Research Organisation)
- Friedrich-Alexander University Erlangen-Nuremberg (Collaboration)
- University of Zurich (Collaboration)
- Eisai Ltd (Collaboration)
- The Wellcome Trust Sanger Institute (Collaboration)
- Helmholtz Association of German Research Centres (Collaboration)
- OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST (Collaboration)
- Jackson Laboratory (Collaboration)
- University of Pennsylvania (Collaboration)
- Goethe University Frankfurt (Collaboration)
- Central Institute for Mental Health (Collaboration)
- Ludwig Maximilian University of Munich (LMU Munich) (Collaboration)
- Hospital de Sant Pau (Collaboration)
- Albert Ludwig University of Freiburg (Collaboration)
- Medical Research Council (MRC) (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- UNIVERSITY OF SOUTHAMPTON (Collaboration)
- University of Bristol (Collaboration)
- University of Manchester (Collaboration)
- University College London (Collaboration)
- UNIVERSITY OF NOTTINGHAM (Collaboration)
- VU University Medical Center (Collaboration)
- National Institute of Health and Medical Research (INSERM) (Collaboration)
- Washington University in St. Louis (Collaboration)
- University Duisburg-Essen (Collaboration)
- Erasmus MC (Collaboration)
- National Center for Biotechnology Information (NCBI) (Collaboration)
- QUEEN'S UNIVERSITY BELFAST (Collaboration)
- Trinity College Dublin (Collaboration)
- Freie Universität Berlin (Collaboration)
- German Centre for Neurodegenerative Diseases (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- UNIVERSITY OF EXETER (Collaboration)
- Genetic Architecture of Rate of Alzheimer’s Decline (GENAROAD) Consortium (Collaboration)
- Universität Hamburg (Collaboration)
- Pasteur Institute, Lille (Collaboration)
- BANGOR UNIVERSITY (Collaboration)
- Mayo Foundation for Medical Education and Research (MFMER) (Collaboration)
- Brigham Young University (Collaboration)
- Genomics England (Collaboration)
- SWANSEA UNIVERSITY (Collaboration)
- National Institutes of Health (NIH) (Collaboration)
- University of Bonn (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
Publications
Ahmad S
(2018)
Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam Study.
in Alzheimer's & dementia : the journal of the Alzheimer's Association
Baker E
(2018)
POLARIS: Polygenic LD-adjusted risk score approach for set-based analysis of GWAS data.
in Genetic epidemiology
Bellenguez C
(2022)
New insights into the genetic etiology of Alzheimer's disease and related dementias.
in Nature genetics
Benitez BA
(2014)
Missense variant in TREML2 protects against Alzheimer's disease.
in Neurobiology of aging
Carpanini SM
(2021)
The Impact of Complement Genes on the Risk of Late-Onset Alzheimer's Disease.
in Genes
Chouraki V
(2016)
Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease.
in Journal of Alzheimer's disease : JAD
| Description | Academy Medical Sciences Council Member |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Description | Academy Medical Sciences Fellow |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Description | Academy Medical Sciences Wales Ambassador |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Description | Associate Director, UK Dementia Research Institute (UKDRI) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Description | COVID advisory group |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Description | Chief Scientific Advisor, Welsh Government |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Description | Deputy Director DPUK |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Membership of a guideline committee |
| Description | EPAD LCS sample access committe |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Description | Medicines Discovery Institute MDI |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Description | NMHRI management |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Description | A high content analysis platform for analysing dementia-associated genetic variation |
| Amount | £108,300 (GBP) |
| Funding ID | ARUK-EG2017A-1 |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 09/2017 |
| Description | Centre for Ageing and Dementia Research (CADR) |
| Amount | £1,200,000 (GBP) |
| Funding ID | 507827 |
| Organisation | Welsh Assembly |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2015 |
| End | 03/2018 |
| Description | Centre for Ageing and Dementia Research - 2 Year Extension |
| Amount | £1,200,000 (GBP) |
| Funding ID | 514840 |
| Organisation | Government of Wales |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2020 |
| Description | The development and implementation of polygenic risk algorithms for stratifying individuals for future cognitive decline due to Alzheimers disease |
| Amount | £298,040 (GBP) |
| Funding ID | 2018/20180222 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 03/2020 |
| Description | Therapeutic targeting of impaired lysosomal flux in Alzheimer's disease |
| Amount | £136,502 (GBP) |
| Funding ID | MR/P007651/1 |
| Organisation | Network of Centres of Excellence in Neurodegeneration (COEN) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 10/2017 |
| Title | AD Genetics Scotland |
| Description | Blood samples are collected from participants and sent directly from research sites to European Collection of Authenticated Cell Cultures (ECACC), a Culture Collection of Public Health England. Upon arrival, ECACC process the blood and transform into cell lines- peripheral blood lymphocytes (PBLs) and Lymphoblastoid cell lines (LCLs). Cell lines are frozen and stored at ECACC until they are required by the team at Cardiff. |
| Type Of Material | Biological samples |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | Ongoing collection of samples, no publications to date. |
| Title | DLB Genetics |
| Description | Blood samples are collected from participants and sent directly from research sites to European Collection of Authenticated Cell Cultures (ECACC), a Culture Collection of Public Health England. Upon arrival, ECACC process the blood and transform into cell lines- peripheral blood lymphocytes (PBLs) and Lymphoblastoid cell lines (LCLs). Cell lines are frozen and stored at ECACC until they are required by the team at Cardiff |
| Type Of Material | Biological samples |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | Ongoing collection of samples, no publications to date |
| Title | EOAD cohort |
| Description | We are collecting a biological sample of early onset Alzheimer's disease individuals for research. This includes phenotypic data and biological data and is set to become the largest EOAD biobank in the world. |
| Type Of Material | Biological samples |
| Provided To Others? | No |
| Impact | This earlier more aggressive form of the disease will be studied in order to shed light on disease mechanisms and prospective therapies. |
| Title | Plcg2 animal models |
| Description | To establish a functional pipeline for the study of disease associated genes and polymorphism in microglia and MØ in the context of dementia-related disease in vivo. The initial concentration is on the impact of coding mutations of PLCG2. In parallel, studies were initated on SPI1 and ABI3. Large scale 'omic and functional assay data derived from these studies will be used to bioinformatically identify potential causative abnormalities, by association with patient data |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | n/a |
| Title | Polygenic score |
| Description | With 80,000 variants included to create a measure of risk of Alzheimer's disease, the polygenic score is an excellent predictive tool to determine case/control status with high accuracy. The polygenic score encompasses the majority of genetic risk of disease, and can be fine-tuned to identify the pathways involved in disease, for example, immune cell activity or endocytosis. |
| Type Of Material | Model of mechanisms or symptoms - human |
| Year Produced | 2016 |
| Provided To Others? | Yes |
| Impact | We are working to translate this method from the basic science environment in which it was created into a predictive tool used to select participants for clinical trials, based on their disease status and type. We are currently in discussions with a number of potential collaborators to take this forward. |
| Title | GERAD Exome chip data |
| Description | Dataset from Illumina Exome chip platform (version 1.0 and v1.1), approximately 6,000 cases and 4,000 controls |
| Type Of Material | Database/Collection of data |
| Year Produced | 2014 |
| Provided To Others? | Yes |
| Impact | papers in press |
| Description | ADES Collaboration |
| Organisation | Erasmus MC |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this. |
| Collaborator Contribution | as above |
| Impact | n/a |
| Start Year | 2016 |
| Description | ADES Collaboration |
| Organisation | Hospital de Sant Pau |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this. |
| Collaborator Contribution | as above |
| Impact | n/a |
| Start Year | 2016 |
| Description | ADES Collaboration |
| Organisation | National Institute of Health and Medical Research (INSERM) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this. |
| Collaborator Contribution | as above |
| Impact | n/a |
| Start Year | 2016 |
| Description | ADES Collaboration |
| Organisation | Pasteur Institute, Lille |
| Country | France |
| Sector | Charity/Non Profit |
| PI Contribution | A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this. |
| Collaborator Contribution | as above |
| Impact | n/a |
| Start Year | 2016 |
| Description | ADES Collaboration |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this. |
| Collaborator Contribution | as above |
| Impact | n/a |
| Start Year | 2016 |
| Description | ADES Collaboration |
| Organisation | University of Bonn |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this. |
| Collaborator Contribution | as above |
| Impact | n/a |
| Start Year | 2016 |
| Description | ADES Collaboration |
| Organisation | University of Pennsylvania |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this. |
| Collaborator Contribution | as above |
| Impact | n/a |
| Start Year | 2016 |
| Description | ADES Collaboration |
| Organisation | VU University Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this. |
| Collaborator Contribution | as above |
| Impact | n/a |
| Start Year | 2016 |
| Description | CADR |
| Organisation | Bangor University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | sample preparation, data analysis |
| Collaborator Contribution | data analysis, sample collections |
| Impact | none yet |
| Start Year | 2014 |
| Description | CADR |
| Organisation | Swansea University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | sample preparation, data analysis |
| Collaborator Contribution | data analysis, sample collections |
| Impact | none yet |
| Start Year | 2014 |
| Description | CFAS |
| Organisation | Bangor University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We are working together with CFAS to prepare the 3,000 participant cohort for genetic research. |
| Collaborator Contribution | Provided cohort |
| Impact | CFAS prepared for Genetic analysis |
| Start Year | 2009 |
| Description | CFAS |
| Organisation | Swansea University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We are working together with CFAS to prepare the 3,000 participant cohort for genetic research. |
| Collaborator Contribution | Provided cohort |
| Impact | CFAS prepared for Genetic analysis |
| Start Year | 2009 |
| Description | EPAD |
| Organisation | GlaxoSmithKline (GSK) |
| Department | Epidemiology |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | GENOTYPING AND ANALYSIS |
| Collaborator Contribution | cohorts, biomarker studies, epidemiological studies, random control studies |
| Impact | none yet |
| Start Year | 2014 |
| Description | Eisai Collaboration |
| Organisation | Eisai Ltd |
| Country | Japan |
| Sector | Private |
| PI Contribution | We are identifying important genes and pathways involved in Alzheimer's disease for further investigation in functional experiments and drug-based tests. |
| Collaborator Contribution | Expertise in functional biology |
| Impact | None yet |
| Start Year | 2015 |
| Description | GENAROAD |
| Organisation | Genetic Architecture of Rate of Alzheimer’s Decline (GENAROAD) Consortium |
| Country | Global |
| Sector | Charity/Non Profit |
| PI Contribution | data and analyses |
| Collaborator Contribution | data analysis |
| Impact | none yet, paper being prepared for publication |
| Start Year | 2013 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Albert Ludwig University of Freiburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Brigham Young University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Central Institute for Mental Health |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Free University of Berlin |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Friedrich-Alexander University Erlangen-Nuremberg |
| Department | Department of Psychiatry |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | German Centre for Neurodegenerative Diseases |
| Country | Germany |
| Sector | Public |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Goethe University Frankfurt |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Helmholtz Association of German Research Centres |
| Department | Helmholtz Zentrum Munchen |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | King's College London |
| Department | Institute of Psychiatry, Psychology & Neuroscience |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Ludwig Maximilian University of Munich (LMU Munich) |
| Department | Department of Neurology |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Mayo Foundation for Medical Education and Research (MFMER) |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Centre for Neuropsychiatric Genetics and Genomics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | National Institutes of Health (NIH) |
| Country | United States |
| Sector | Public |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Oxford University Hospitals NHS Foundation Trust |
| Department | NIHR Oxford Biomedical Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Queen's University Belfast |
| Department | Aging group |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Trinity College Dublin |
| Country | Ireland |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University College London |
| Department | Institute of Neurology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University College London |
| Department | MRC Prion Unit and the Dementia Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University Duisburg-Essen |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University of Bonn |
| Department | Department of Psychiatry |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University of Bristol |
| Department | Dementia Research Group |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University of Cambridge |
| Department | Cambridge Institute of Public Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University of Hamburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University of Manchester |
| Department | Neuroscience Research Institute (NRI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University of Nottingham |
| Department | Centre for Genetics and Genomics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University of Southampton |
| Department | Clinical and Experimental Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | University of Zurich |
| Department | Functional Genomics Centre Zurich |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | GERAD (Genetic and Environmental Risk in Alzheimer's Disease) |
| Organisation | Washington University in St Louis |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers |
| Collaborator Contribution | DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation |
| Impact | Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934 |
| Start Year | 2008 |
| Description | Genome-wide Association Studies |
| Organisation | National Center for Biotechnology Information (NCBI) |
| Country | United States |
| Sector | Public |
| PI Contribution | Led and co-ordinated the study that involved the work of the following collaborators: 1 MRC Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK. 2 NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, Kings College, London, UK. 3 Department of Neuroscience, Institute of Psychiatry, Kings College, London, UK. 4 Institute of Public Health, University of Cambridge, Cambridge, UK. 5 Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK. 6 Mercer's Institute for Research on Aging, St. James Hospital and Trinity College, Dublin, Ireland. 7 Institute of Genetics, Queen's Medical Centre, University of Nottingham, NG7 2UH, UK. 8 Ageing Group, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, UK. 9 Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK. 10 Clinical Neuroscience Research Group, Greater Manchester Neurosciences Centre, University of Manchester, Salford, UK. 11 Oxford Project to Investigate Memory and Ageing (OPTIMA), University of Oxford, Level 4, John Radcliffe Hospital, Oxford OX3 9DU, UK. 12 Dementia Research Group, University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, Bristol, UK. 13 Department of Molecular Neuroscience and Reta Lilla Weston Laboratories, Institute of Neurology, London, UK. 14 MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK. 15 Dementia Research Centre, Department of Neurodegenerative Diseases, University College London, Institute of Neurology, London, UK. 16 Department of Psychiatry, University of Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany. 17 Institute of Primary Medical Care, University Medical Center Hamburg-Eppendorf, Germany. 18 Department of Psychiatry, Charité Berlin, Germany. 19 Department of Psychiatry and Psychotherapy, University of Erlangen-Nüremberg, Germany. 20 LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, University Duisburg-Essen, Germany. 21 Institute for Stroke and Dementia Reserach, Klinikum der Universität München, Marchioninistr. 15, 81377, Munich, Germany. 22 Department of Neurology, Klinikum der Universität München, Marchioninistr. 15, 81377, Munich, Germany. 23 Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Square J5, D-68161 Mannheim, Germany. 24 Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Laboratory of Neuroimaging & Biomarker Research, Trinity College, University of Dublin, Ireland. 25 Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig-Maximilian University, Munich, Germany. 26 Centre for Geriatric Medicine and Section of Gerontopsychiatry and Neuropsychology, Medical School, University of Freiburg, Germany. 27 Departments of Psychiatry, Neurology and Genetics, Washington University School of Medicine, St Louis, MO 63110, US. 28 Department of Biology, Brigham Young University, Provo, UT, 84602, USA. 29 Neurodegenerative Brain Diseases group, Department of Molecular Genetics, VIB, Antwerpen, Belgium. 30 Institute Born-Bunge and University of Antwerp; Antwerpen, Belgium. 31 Memory Clinic and Department of Neurology, ZNA Middelheim, Antwerpen, Belgium. 32 Department of Mental Health Sciences, University College London, UK. 33 The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK. 34 MRC Centre for Neurodegeneration Research, Department of Clinical Neuroscience, King's College London, Institute of Psychiatry, London, SE5 8AF, UK. 35 3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece. 36 Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892, USA. 37 Department of Genomics, Life & Brain Center, University of Bonn, Sigmund-Freud-Str. 25, D-53127 Bonn, Germany. 38 Institute of Human Genetics, University of Bonn, Wilhelmstr. 31, D-53111 Bonn, Germany. 39 Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, University Duisburg-Essen, Hufelandstr. 55, D-45147 Essen, Germany. 40 Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany. 41 Institute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany. 42 Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida 32224, USA. 43 Division of Biomedical Statistics and Informatics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA |
| Collaborator Contribution | This group of 45 collaborators all contributed towards the centres Genome-wide association study |
| Impact | The study, published in Nature Genetics (PubMed ID 19734902), has uncovered two new genes associated with Alzheimer's disease. Previously only one gene, APOE4, had been shown to be a risk factor for Alzheimer's disease. The study reveals, for the first time, that two further genes, CLU and PICALM, are related to Alzheimer's disease. This has led to worldwide media coverage. The data produced is still used in new studies with requests coming in to the host institution every few weeks. |
| Start Year | 2009 |
| Description | Genomics England |
| Organisation | Genomics England |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | We are in the very early stages of discussion with Genomics England, but we hope to be able to use their facilities for whole Genome sequencing. This will mean that we generate valuable data on the largest EOAD cohort world-wide. |
| Collaborator Contribution | Genomics England have the equipment and infrastructure set up for the very expensive and technical whole exome sequencing. |
| Impact | None yet |
| Start Year | 2015 |
| Description | GlaxoSmithKline Cardiff Collaboration |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Prof Williams made contact with a GSK rep at the Global Genetics Congress in Baltimore, September 2016. GSK were extremely interested in collaborating with the Cardiff team. Specifically, GSK have an interest in the latest confidential experimental results and translating these from genetic to biological meaning. This will speed up the Cardiff Team's discovery of potential molecular targets for personalised disease treatment. Cardiff will contribute expertise in Alzheimer's disease genetics. |
| Collaborator Contribution | GSK will contribute their expertise in disease models and drug mechanisms. |
| Impact | This collaboration has been brought under a confidentiality agreement. Parties involved are experts in genetics and functional biology. |
| Start Year | 2016 |
| Description | Jackson labs collaboration |
| Organisation | The Jackson Laboratory |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | We provide the most up to date genetic human Alzheimer's disease study results and interpretation. |
| Collaborator Contribution | Jackson labs provide their expertise in translation of human study findings into small animal transgenic models of genetic diseases. |
| Impact | Attempts so far to tie down both a project plan and committed funding, have not been successful. We are currently exploring alternative methods to whole animal experiments. We hope that in the future we will be able to regenerate interest in this promising collaboration. |
| Start Year | 2016 |
| Description | MRC AD Cohort |
| Organisation | King's College London |
| Department | Institute of Psychiatry, Psychology & Neuroscience |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis. |
| Collaborator Contribution | The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. |
| Impact | 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421 |
| Description | MRC AD Cohort |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Centre for Developmental Neurobiology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis. |
| Collaborator Contribution | The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. |
| Impact | 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421 |
| Description | MRC AD Cohort |
| Organisation | Trinity College Dublin |
| Country | Ireland |
| Sector | Academic/University |
| PI Contribution | We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis. |
| Collaborator Contribution | The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. |
| Impact | 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421 |
| Description | MRC AD Cohort |
| Organisation | University of Cambridge |
| Department | Department of Medical Genetics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis. |
| Collaborator Contribution | The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. |
| Impact | 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421 |
| Description | MRC AD Cohort |
| Organisation | University of Cambridge |
| Department | Department of Public Health and Primary Care |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis. |
| Collaborator Contribution | The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. |
| Impact | 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421 |
| Description | PROTECT / CHARIOT-Pro / Cardiff DPUK |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Genotyping of 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be completed by Cardiff Univ as part of a collaboration funded by Dementias Platform UK. Polygenic risk scores will be calculated for these individuals and data made available via DPUK Platform. |
| Collaborator Contribution | DNA samples from 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be sent to Cardiff Univ for genotyping |
| Impact | None to date - work in progress. Collaboration is multi-disciplinary - Neurology, Neuroepidemiology & Ageing; Genetics & Genomics; Psychiatry |
| Start Year | 2018 |
| Description | PROTECT / CHARIOT-Pro / Cardiff DPUK |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Genotyping of 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be completed by Cardiff Univ as part of a collaboration funded by Dementias Platform UK. Polygenic risk scores will be calculated for these individuals and data made available via DPUK Platform. |
| Collaborator Contribution | DNA samples from 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be sent to Cardiff Univ for genotyping |
| Impact | None to date - work in progress. Collaboration is multi-disciplinary - Neurology, Neuroepidemiology & Ageing; Genetics & Genomics; Psychiatry |
| Start Year | 2018 |
| Description | PROTECT / CHARIOT-Pro / Cardiff DPUK |
| Organisation | University of Exeter |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Genotyping of 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be completed by Cardiff Univ as part of a collaboration funded by Dementias Platform UK. Polygenic risk scores will be calculated for these individuals and data made available via DPUK Platform. |
| Collaborator Contribution | DNA samples from 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be sent to Cardiff Univ for genotyping |
| Impact | None to date - work in progress. Collaboration is multi-disciplinary - Neurology, Neuroepidemiology & Ageing; Genetics & Genomics; Psychiatry |
| Start Year | 2018 |
| Title | DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE |
| Description | The invention relates to novel variants that associate with Alzheimer's disease AD and their use in kits as a means for diagnosing AD; and also their use in nucleic acid molecules or cells/cell lines for identifying novel therapeutic, label of identification means. |
| IP Reference | WO2011001135 |
| Protection | Patent granted |
| Year Protection Granted | 2011 |
| Licensed | No |
| Impact | This has had huge worldwide impact through media coverage and was originally highlighted in the press with the discovery of an additional 5 genes. We are currently in the process of seeking a licencee for the patented technology which encompasses a diagnostic test for the protected gene SNPs. Recent advances include generation of a polygenic score including the licensed SNPs for the detection of AD risk. We are working together with industry on basic genetic testing, cohort studies, cognitive te |
| Description | AAIC Los Angeles Annual Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | MODEL-AD presentation - Alzheimer's Susceptibility Genes Implicate Microglial Activity |
| Year(s) Of Engagement Activity | 2019 |
| Description | AMS fellowship workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Organisation of a Academy of Medical Science workshop by J Williams as Wales AMS Champion to encourage applications from young researchers to become AMS fellows |
| Year(s) Of Engagement Activity | 2019 |
| Description | ARUK Conference |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Attendee at online conference |
| Year(s) Of Engagement Activity | 2022 |
| Description | ARUK network 2019 Exeter |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | The event was organised between the ARUK Bristol & Bath, Southwest (Exeter and Plymouth) and Wales networks. The aim was for members to meet, showcase research & build collaborations. J Williams spoke on Research infrastructure and resources: UKDRI as member of Cardiff University and UK Brain Banks Network |
| Year(s) Of Engagement Activity | 2019 |
| Description | Alzheimer's gene study achieves landmark breakthrough |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Cardiff University publicised publication in Nature Genetics "Genetic meta-analysis of diagnosed Alzheimer's disease identifies novel risk loci and implicates Abeta, Tau, immunity and lipid processing" - aiming to raise public awareness of research being undertaken at UK Dementia Research Institute Cardiff |
| Year(s) Of Engagement Activity | 2019 |
| Description | BBC Wales evening news UK DRI Cardiff official opening |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Interview of Professor Julie Williams to publicise official opening of UK DRI Cardiff. Prof Williams explained the purpose of the DRI, its multi-targeted approach, and the funding that had enabled attraction of world class scientists to Cardiff. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.bbc.co.uk/iplayer/episode/b0bp0k0t/bbc-wales-today-evening-news-25102018# |
| Description | BBC radio interview |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Radio interview BBC Forty research groups led by scientists in Cardiff, France and the United States have been working more closely together and have now pooled a worldwide database of 90,000 samples. "We're about to submit a paper that is enormously exciting and which I think will really change, without a doubt, what we think of Alzheimer's disease going forward," Professor Julie Williams, head of the research team at Cardiff University, said. "Over the last five or six years we've been successful in identifying 30 genes that increase - or decrease - your risk for Alzheimer's disease. Now this is telling us what some of the major components in disease development are. It's new, it's exciting; it's a different perspective on what Alzheimer's disease is." |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://www.bbc.co.uk/news/uk-wales-36286847 |
| Description | Best Paper of 2022 meeting |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Meeting to discuss paper that was deemed the best of 2022 |
| Year(s) Of Engagement Activity | 2022 |
| Description | Brain Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Invited speaker |
| Year(s) Of Engagement Activity | 2022 |
| Description | Brain Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | The Guarantors of Brain was set up to promote teaching, education and research in neurology and related disciplines. In 2021, we put on our first conference - run as a 2-day online conference, with a focus on clinical neurology and research. The conference was attended by almost 2000 delegates across the globe. |
| Year(s) Of Engagement Activity | 2022 |
| Description | CURE ND Workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Workshop to discuss disease models in the field of neurodegeneration, what are the most advanced models to date, how accurate are they, and what is missing in terms of modelling |
| Year(s) Of Engagement Activity | 2021 |
| Description | Cheltenham Science Festival |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | The Festival theme 2019 was health and wellbeing, considering everything from the food we eat and our exercise regimes to cutting-edge medical research. As part of this theme, the event explored the latest breakthroughs in dementia research. The panel was asked to talk about the broad landscape in this field and its evolution in recent years, key achievements and challenges and an insight into how the diagnosis and treatment of dementia has changed and developed. J Williams talked about cutting-edge research and expertise and the exciting aspects of her own work within this area As populations have aged, dementia has become the fifth biggest cause of death worldwide. Yet despite its devastating consequences there is currently no cure. What do we know about this group of diseases, and are there things we can do to help reduce our risks and keep our brains fighting fit? Alzheimer's disease specialist Julie Williams and psychiatrist Ivan Koychev discuss the latest breakthroughs and discoveries that are helping to prevent, diagnose and treat dementia more effectively. |
| Year(s) Of Engagement Activity | 2011,2019 |
| Description | Insurance United Against Dementia |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | Alzheimer's Society Insurance United Against Dementia campaign dinner - aim to formally launch IUAD partners to senior figureheads from the insurance industry Used as an opportunity to thank existing IUAD partners and inspire potential partners to make a contribution. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Interview for national news |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Interview on national TV which is broadcast worldwide describing set up of Cardiff Univ receiving funding to set up as a UK dementia centre |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://www.bbc.co.uk/news/uk-wales-south-east-wales-39646667 |
| Description | Interview for national news |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Official opening of UK DRI Cardiff, attended by 300+ guests, including funders, Welsh government officials, members of the public taking part in dementia research studies, postgraduates. Widely publicised on national BBC and ITV news and radio |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.bbc.co.uk/news/uk-wales-45942094 |
| Description | Interview for regional news |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Interview on regional news to discuss setting up of new DRI UK laboratories in Cardiff and work on dementia research |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://www.itv.com/news/wales/2017-04-20/dementia-centre-to-offer-step-change-in-research/ |
| Description | Interview with BBC |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Interview with BBC - Alzheimer's article |
| Year(s) Of Engagement Activity | 2022 |
| Description | Keynote speech Sutcliffe Kerr Lecture |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Keynote speech at annual Walton Centre, Sutcliffe Kerr Lecture |
| Year(s) Of Engagement Activity | 2019 |
| Description | Local news item on brain donation for dementia research |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Older people in Wales are being urged to think about donating their brains after they die to help scientists researching dementia. This has sparked questions and debates - 80 comments within 24 hours. It will definitely influence people by raising awareness of the disease, the process of donation, benefits of donation/research and also opting in/out law change. We are confident this will increase the number of healthy/diseased donations and positively impact research field. |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://www.bbc.co.uk/news/uk-wales-43084710 |
| Description | MRC CNGG celebration event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | MRC CNGG celebration - presentation and video |
| Year(s) Of Engagement Activity | 2019 |
| Description | Medical Women's Federation Spring Conference 2018 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation on 'Finding the causes of Alzheimer's disease' |
| Year(s) Of Engagement Activity | 2018 |
| Description | Quote for This is Wales publication |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Quotation provided on the subject of innovation in Wales for trade magazine, emphasising research focus on dementia, specifically Alzheimer's disease |
| Year(s) Of Engagement Activity | 2018 |
| Description | RCPsych Neuropsychiatry Annual Conference 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk given to conference entitled "Neuropsychiatric Genetics of Dementia and other Neurodegenerative Disorders: Implications for treatment, prevention and personalised psychiatry" |
| Year(s) Of Engagement Activity | 2019 |
| Description | Radio Interview with Alz Res UK Champion |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Radio Gloucester interview with Sue Strachan Alz Res UK Champion |
| Year(s) Of Engagement Activity | 2021 |
| Description | Radio interview |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Radio 4 interview for the programme The Life Scientific |
| Year(s) Of Engagement Activity | 2023 |
| Description | Recorded interview ARUK conference March 2018 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | An interview with Video Journal Dementia at ARUK Conference 2018 discussing work at Cardiff DRI UK - online publication aimed at healthcare professionals |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://vjdementia.com/speaker/julie-williams |
| Description | Taking a new look at the risk factors for Alzheimer's disease |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Media article on publication of Multiplex Model in Nature Neuroscience - providing information on how the genes that have been identified as risk factors impact on other genes to trigger Alzheimer's |
| Year(s) Of Engagement Activity | 2020 |
| Description | Techniquest 55+Science Cafe Launch |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Supporters |
| Results and Impact | Invited speaker |
| Year(s) Of Engagement Activity | 2022 |
| Description | UK Biobank Winter Scientific Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Invited speaker to conference in London |
| Year(s) Of Engagement Activity | 2022 |
| Description | UK Korea Neuroscience Symposium |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | UKorea symposia bridge basic and clinical research within neuroscience. J Williams gave plenary lecture on 1st day 2019 symposium. The statements were shared via the UK-Korea social media channel (twitter @UKorea_Neuro). |
| Year(s) Of Engagement Activity | 2019 |
| Description | Visit by Lord Mayor of Cardiff to DRI |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | Visit by Lord Mayor of Cardiff to Dementia Research Institute |
| Year(s) Of Engagement Activity | 2022 |
| Description | Visit by Ruth Jones MP to DRi |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | Ruth Jones MP visited Dementia Research Institute Cardiff |
| Year(s) Of Engagement Activity | 2022 |
| Description | Visit of Jo Stephens MP to DRI |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | Visit by Jo Stephens MP to Cardiff Dementia Research Institute |
| Year(s) Of Engagement Activity | 2022 |
| Description | Visit to DRI laboratories by Sir Venki Ramakrishnan |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Sir Venki Ramakrishnan, the President of the Royal Society visited DRI laboratories, Cardiff on 23rd October prior to giving a lecture organised by Welsh Government |
| Year(s) Of Engagement Activity | 2019 |
| Description | Welsh Government workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | The Welsh Government held a UKRI "Strength in Places Fund" and potential for Wales workshop. Strength in Places (SIP) offers a significant funding opportunity and the University is keen to prepare a pipeline of projects for development in this area, in what is anticipated, to be an annual call. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Will members of my family develop Alzheimers disease?' |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Dr Rebecca Sims presented "Will members of my family develop Alzheimer's disease?" at CADR Meeting Swansea, 2/8/2018. This reached an audience of 50 persons including general public, medical professionals, researchers and carers. This generated a number of questions and discussion after the talk, and was part of a wider discussion following other presentations focusing on similar topics. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Women in Industry |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Industry/Business |
| Results and Impact | Presentation to Women in Industry event, providing overview of career, advice for women in STEM careers |
| Year(s) Of Engagement Activity | 2019 |
| Description | Women in Science film |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Women in Science video as one of the interviewees / case studies. |
| Year(s) Of Engagement Activity | 2019 |
| Description | World Dementia Conference - speaker |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | This WDC summit meeting was focused on 'Looking to the Future: The Dementia landscape' and followed the series of global dialogues as part of the WDC's dementia landscape project. Discussion took place on the science and research agenda and built on previous conversations of international dementia leaders around innovation and incentives and data sharing. As a guest speaker, asking the question 'are we on track', we explored whether the research and policy landscape facilitating the development of new treatments required global co-ordination, considered whether the right things are being funded and whether new funding models were required. |
| Year(s) Of Engagement Activity | 2021 |
| Description | World Dementia Council |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Speaker |
| Year(s) Of Engagement Activity | 2022 |